Galapagos' GLPG1205 fails in Phase IIa UC trial

Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG) said it will discontinue development of GLPG1205 to treat ulcerative colitis after the compound missed the efficacy endpoints in the Phase IIa ORIGIN trial. GLPG1205 did not significantly improve Mayo scores from baseline compared with placebo.

Galapagos had planned to seek a partner for the G protein-coupled receptor 84 ( GPR84) inhibitor. The company said Tuesday it will evaluate whether to develop GLPG1205 for other indications. ...